Validation of a novel NGS based BCR::ABL1 kinase domain mutation detection assay in Indian cohort
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Validation of a novel NGS based BCR::ABL1 kinase domain mutation detection assay in Indian cohort ; volume:14 ; number:1 ; day:8 ; month:7 ; year:2024 ; pages:1-14 ; date:12.2024
Scientific reports ; 14, Heft 1 (8.7.2024), 1-14, 12.2024
- Urheber
-
Chaudhary, Pooja
Chaudhary, Spandan
Patel, Falguni
Patel, Shiv
Vaishnani, Toral
Trivedi, Nikha
Patel, Dhiren
Sonagara, Tushar
Hirapara, Ashish
Vyas, Kavisha
Patel, Lokesh
Kumar, Raja
Chakraborty, Nikkan
Sharma, Divya
Suthar, Jigar
Kamdar, Payal
Jajodia, Ekta
Ahmad, Firoz
Arora, Neeraj
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-66310-8
- URN
-
urn:nbn:de:101:1-2409252131580.038286043631
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chaudhary, Pooja
- Chaudhary, Spandan
- Patel, Falguni
- Patel, Shiv
- Vaishnani, Toral
- Trivedi, Nikha
- Patel, Dhiren
- Sonagara, Tushar
- Hirapara, Ashish
- Vyas, Kavisha
- Patel, Lokesh
- Kumar, Raja
- Chakraborty, Nikkan
- Sharma, Divya
- Suthar, Jigar
- Kamdar, Payal
- Jajodia, Ekta
- Ahmad, Firoz
- Arora, Neeraj
- SpringerLink (Online service)
Ähnliche Objekte (12)
Development of mirror-image monobodies targeting the oncogenic BCR::ABL1 kinase
Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien
BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling
Die duale Hemmung der BCR-ABL1 Kinase und des Proteasoms als neuer Therapieansatz in der BCR-ABL positiven akuten lymphatischen Leukämie
FISH mapping of Philadelphia negative BCR/ABL1 positive CML
Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1
Development of mirror-image monobodies targeting the oncogenic BCR::ABL1 kinase
Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien
BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling
Die duale Hemmung der BCR-ABL1 Kinase und des Proteasoms als neuer Therapieansatz in der BCR-ABL positiven akuten lymphatischen Leukämie
FISH mapping of Philadelphia negative BCR/ABL1 positive CML
Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1
Development of mirror-image monobodies targeting the oncogenic BCR::ABL1 kinase
Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien
BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling
Die duale Hemmung der BCR-ABL1 Kinase und des Proteasoms als neuer Therapieansatz in der BCR-ABL positiven akuten lymphatischen Leukämie
FISH mapping of Philadelphia negative BCR/ABL1 positive CML
Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells